Why Are Eligible Thrombolysis Candidates Left Untreated?

American Journal of Preventive Medicine

Volumn 31, Issue 6 SUPPL. 2, 2006, Pages

  Hills, Nancy K ^a   Johnston, S Claiborne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HOSPITAL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RISK FACTOR; SYMPTOM; TREATMENT CONTRAINDICATION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CALIFORNIA; CEREBROVASCULAR ACCIDENT; DECISION MAKING; DRUG UTILIZATION REVIEW; EMERGENCY SERVICE, HOSPITAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33845407453     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2006.08.004     Document Type: Article

References (24)

1. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 483S-512S
2. Kwiatkowski T.G., Libman R.B., Frankel M., et al., National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 340 (1999) 1781-1787
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
4. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory: thrombolytic therapy for acute ischemic stroke-summary statement. Neurology 47 (1996) 835-839
5. Adams H.P., Brott T.G., Furlan A.J., et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 94 (1996) 1167-1174
6. Chiu D., Krieger D., Villar-Cordova C., et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 29 (1998) 18-22
7. Zweifier R., Brody M., Graves G., et al. Intravenous tPA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology 50 (1998) 501-503
8. Hacke W., Brott T., Caplan L., et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53 7 suppl 4 (1999) S3-S14
9. Katzan I.L., Furlan A.J., Lloyd L.E., et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283 (2000) 1151-1158
10. Kleindorfer D., Khoury J., Alwell K., et al. RtPA use in a population-based study: the post-FDA approval era. Stroke 34 suppl (2003) 283
11. Tanne D., Gorman M., Bates V., et al. Intravenous tissue plasminogen activator for acute ischemic stroke patients aged 80 years and older. The tPA stroke survey experience. Stroke 31 (2000) 370-375
12. Muir K., and Roberts M. Thrombolytic therapy for stroke: a review with particular reference to elderly patients. Drugs Aging 16 (2000) 41-54
13. Tanne D., Turgeman D., and Adler Y. Management of acute ischaemic stroke in the elderly: tolerability of thrombolytics. Drugs 61 (2001) 1439-1453
14. Berrouschot J., Rother J., Glahn J., et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≤80 years) stroke patients. Stroke 36 (2005) 2421-2425
15. Sylaja P.N., Cote R., Buchan A.M., et al. Thrombolysis for acute ischemic stroke patients aged 80 years and older: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 77 (2006) 826-829
16. Johnston S.C., Fung L.H., Gillum L.A., et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 32 (2001) 1061-1068
17. Barber P.A., Zhang J., Demchuk A.M., et al. Why are stroke patients excluded from TPA therapy?. An analysis of patient eligibility. Neurology 56 (2001) 1015-1020
18. California Acute Stroke Pilot Registry. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 64 (2005) 654-659
19. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory: thrombolytic therapy for acute ischemic stroke-summary statement. Neurology 47 320 (1996) 835-839
20. O'Connor R.E., McGraw P., and Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 33 (1999) 9
21. Kleindorfer D., Kissela B., Schneider A., et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 35 (2004) e27-e29
22. Albers G.W., Bates V.E., Clark W.M., et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150
23. McCormick M.T., and Muir K.W. Referral bias may underestimate number of very elderly patients eligible for rtPA. Stroke 37 (2006) 942-943
24. Katzan I.L., Hammer M., Hixson E., et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 61 (2004) 346-350